Cristina Castillo

Ms. Cristina Castillo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2025 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
WHWesley Huang
Wesley Huang
YZYuezhong Zhang
Yuezhong Zhang
NDNupur Das
Nupur Das
SSSumeet Solanki
Sumeet Solanki
CJChesta Jain
Chesta Jain
YSYatrik Shah
Yatrik Shah

19 May 2025 in Cancer Research
Verified
Journal Article
Closed access
SDStephen L. DeAngelo
Stephen L. DeAngelo
LZLiang Zhao
Liang Zhao
SDSofia Dziechciarz
Sofia Dziechciarz
MSMyungsun Shin
Myungsun Shin
SSSumeet Solanki
Sumeet Solanki
YSYatrik Shah
Yatrik Shah
Ferroptosis is a nonapoptotic form of cell death driven by iron-dependent lipid peroxide accumulation. Colorectal cancer cells feature elevated intracellular iron and reactive oxygen species that heighten ferroptosis sensitivity. The ferroptosis inducer (S)-RSL3 [(1S,3R)-RSL3] is widely described as a selective inhibitor of the selenocysteine-containing enzyme (selenoprotein) glutathione peroxidase 4 (GPX4), which detoxifies lipid peroxides using glutathione. However, through chemical controls using the (R) stereoisomer of RSL3 [(1R,3R)-RSL3] that does not bind GPX4, combined with inducible genetic knockdowns of GPX4 in colorectal cancer cell lines, we revealed in this study that GPX4 dependency does not always align with (S)-RSL3 sensitivity, thereby questioning the current characterization of GPX4 as the primary target of (S)-RSL3. Affinity pull-down mass spectrometry with modified (S)-RSL3 probes identified multiple selenoprotein targets, indicating broad selenoprotein inhibition. Further investigation of the therapeutic potential of broadly disrupting the selenoproteome as a therapeutic strategy in colorectal cancer showed that the selenoprotein inhibitor auranofin, an FDA-approved gold salt, chemically induced oxidative cell death and ferroptosis in colorectal cancer models in vitro and in vivo. Similarly, genetic perturbation of ALKBH8, a tRNA-selenocysteine methyltransferase required for selenoprotein translation, suppressed colorectal cancer growth. In summary, these findings recharacterize the mechanism of (S)-RSL3 beyond GPX4 inhibition and establish selenoproteome disruption as a colorectal cancer therapeutic strategy. Significance: Chemoproteomic profiling reveals that RSL3 functions through pan-selenoprotein inhibition beyond GPX4 and identifies ALKBH8, a tRNA-selenocysteine methyltransferase essential for selenoprotein translation, as a therapeutic target to disrupt redox balance in colorectal cancer. See related commentary by Short, p. 2775

1 August 2025
Verified
Other
Open access
SDStephen L. DeAngelo
Stephen L. DeAngelo
LZLiang Zhao
Liang Zhao
SDSofia Dziechciarz
Sofia Dziechciarz
MSMyungsun Shin
Myungsun Shin
SSSumeet Solanki
Sumeet Solanki
YSYatrik Shah
Yatrik Shah
Supplementary Figure S4 provides CETSA data to illustrate the absence of direct GPX4 interaction with the compound auranofin in treated cells.

1 August 2025
Verified
Other
Open access
SDStephen L. DeAngelo
Stephen L. DeAngelo
LZLiang Zhao
Liang Zhao
SDSofia Dziechciarz
Sofia Dziechciarz
MSMyungsun Shin
Myungsun Shin
SSSumeet Solanki
Sumeet Solanki
YSYatrik Shah
Yatrik Shah
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.

1 August 2025
Verified
Other
Open access
SDStephen L. DeAngelo
Stephen L. DeAngelo
LZLiang Zhao
Liang Zhao
SDSofia Dziechciarz
Sofia Dziechciarz
MSMyungsun Shin
Myungsun Shin
SSSumeet Solanki
Sumeet Solanki
YSYatrik Shah
Yatrik Shah
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.

22 January 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
CCCristina Castillo
Cristina Castillo
SGSharon B Gim
Sharon B Gim
NDNupur Das
Nupur Das
Background/Objectives: The hepcidin–ferroportin (Fpn1) axis is central to intestinal iron absorption, and dysregulation of this axis underlies all known forms of iron disorders. Hemochromatosis, the most common iron overload disorder in humans, results from systemic iron accumulation due to decades of uncontrolled intestinal absorption. Despite major advances in medicine in recent years, strategies for iron overload management are still lagging as they primarily rely on iron chelation and repeated phlebotomies. Fpn1, the cellular iron exporter, is ubiquitously expressed and plays a critical role in maintaining systemic iron homeostasis. Methods: To investigate the specific contribution of intestinal Fpn1 to systemic iron overload, we employed a CRISPR-based adenoviral hepcidin knockout mediated mouse iron overload model, combined with intestine-specific deletion of Fpn1. Results: An initial time-dependent experiment establishes the efficiency of hepcidin knockout (KO) by as early as 1 week of adenovirus injection. At 2 weeks of injection, a perfect reciprocal relationship between hepcidin gene suppression and liver iron levels (5–7-fold induction from the baseline) was established. Finally, intestine-specific Fpn1 deletion effectively prevented iron accumulation in hepcidin KO mice, as evidenced by nearly 4-fold lower liver iron levels compared to hepcidin KO animals with intact intestinal Fpn1. Conclusions: In summary, our results demonstrate that ablation of intestinal Fpn1 is sufficient to attenuate systemic iron accumulation in this mouse model of hemochromatosis. These findings suggest that selective targeting of intestinal Fpn1 may represent a promising strategy for the management of iron overload.